Erick Suarez
Infectious Disease · Orlando, FLNPI 1215442223
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Viiv Healthcare Company at 49.7% of the total. 2025 is the largest year on record at $50,203, more than ten times the $317 reported in 2021. Among infectious disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 460 payments — averaging $248.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$57K
- Gilead$52K
- Merck$2K
- AbbVie$469
- Alkermes, Inc.$360
- Napo Pharmaceuticals Inc$346
- plus $2K from 16 others
Across 2 payments — averaging $6487.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$13K
What the payments were for
- Consulting fees$15,01513%
- Speaking & faculty fees$63,31255%
- Travel & lodging$24,35721%
- Food & beverage$11,57710%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 150 | $56,879 |
| Gilead | 171 | $52,471 |
| Merck | 20 | $1,809 |
| AbbVie | 26 | $469 |
| Alkermes, Inc. | 13 | $360 |
| Napo Pharmaceuticals Inc | 10 | $346 |
| Johnson & Johnson | 20 | $339 |
| Axsome Therapeutics, Inc. | 6 | $234 |
| Novo Nordisk | 7 | $229 |
| Janssen Products, LP | 2 | $222 |
| Janssen Scientific Affairs, LLC | 4 | $148 |
| Antares Pharma, Inc. | 2 | $146 |
| Lilly USA, LLC | 7 | $129 |
| Theratechnologies Inc. | 5 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $99 |
| Hologic Sales And Service, LLC | 2 | $91 |
| Biogen | 1 | $83 |
| Abbott | 4 | $72 |
| Tolmar, Inc. | 2 | $38 |
| Boston Scientific | 1 | $28 |
| Exact Sciences | 1 | $25 |
| Galderma Laboratories, L.p. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,361 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 21 | $95,763 |
| DescovyEmtricitabine/Tenofov Alafenam | 20 | $53,702 |
| TivicayDolutegravir Sodium | 13 | $49,640 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,022 |
| OzempicSemaglutide | 23 | $40,692 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $40,443 |
| Carbamazepine | 12 | $291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy, Genvoya, Biktarvy | $52,471 | $142,16743 claims |
| Janssen Products, LPSymtuza | $222 | $95,76321 claims |
| Viiv Healthcare CompanyTivicay | $56,879 | $49,64013 claims |
| Novo NordiskOzempic | $229 | $40,69223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Orlando
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Federico HinestrosaOrlando$276K
- Vincent HsuOrlando$222K
- Roberto OrtizOrlando$71K
- Edwin DejesusOrlando$42K
- Patricia CoutoOrlando$28K
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.